Reducing levels of amyloid-B, the peptide that accumulates and causes Alzheimer's disease, is the most likely method to treat or prevent this disease. Our preliminary data demonstrates that postsynaptic signaling mechanisms, mainly through NMDA and orexin receptors, can dramatically reduce AB production and levels. We propose that both of these neurotransmitter systems activate substantially different signaling cascades that eventually converge on the extracellular-regulated kinase (ERK) signaling pathway. Activation of the ERK signaling cascade rapidly and dramatically reduces AB levels in vivo. This proposal will determine the cellular pathways that link these neurotransmitter receptors to ERK and AB metabolism. Understanding these pathways will provide insight into factors that contribute to disease risk as well as provide new pathways that could be targeted for therapeutic inten/enfion to treat AD.
Reducing levels of amyloid-B (AB), the peptide that accumulates and causes Alzheimer's disease, is the most likely method to treat or prevent this disease. Our preliminary data demonstrates that certain neurotransmitter receptors can reduce AP levels in living mice. This proposal will determine the cellular pathways that link these receptors to Ap metabolism. This could lead to new avenues for therapeutic intervention
| Zhao, Na; Liu, Chia-Chen; Qiao, Wenhui et al. (2018) Apolipoprotein E, Receptors, and Modulation of Alzheimer's Disease. Biol Psychiatry 83:347-357 |
| Musiek, Erik S; Bhimasani, Meghana; Zangrilli, Margaret A et al. (2018) Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease. JAMA Neurol 75:582-590 |
| Kress, Geraldine J; Liao, Fan; Dimitry, Julie et al. (2018) Regulation of amyloid-? dynamics and pathology by the circadian clock. J Exp Med 215:1059-1068 |
| Ogaki, Kotaro; Martens, Yuka A; Heckman, Michael G et al. (2018) Multiple system atrophy and apolipoprotein E. Mov Disord 33:647-650 |
| Liao, Fan; Li, Aimin; Xiong, Monica et al. (2018) Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. J Clin Invest 128:2144-2155 |
| Kang, S S; Ren, Y; Liu, C-C et al. (2018) Lipocalin-2 protects the brain during inflammatory conditions. Mol Psychiatry 23:344-350 |
| Hettinger, Jane C; Lee, Hyo; Bu, Guojun et al. (2018) AMPA-ergic regulation of amyloid-? levels in an Alzheimer's disease mouse model. Mol Neurodegener 13:22 |
| Yuede, Carla M; Timson, Benjamin F; Hettinger, Jane C et al. (2018) Interactions between stress and physical activity on Alzheimer's disease pathology. Neurobiol Stress 8:158-171 |
| Liu, Chia-Chen; Hu, Jin; Zhao, Na et al. (2017) Astrocytic LRP1 Mediates Brain A? Clearance and Impacts Amyloid Deposition. J Neurosci 37:4023-4031 |
| Holth, Jerrah; Patel, Tirth; Holtzman, David M (2017) Sleep in Alzheimer's Disease - Beyond Amyloid. Neurobiol Sleep Circadian Rhythms 2:4-14 |
Showing the most recent 10 out of 85 publications
